Want to see HK:3692 full AI Analyst Report?
Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Select Model
Select Model
Rating:75Outperform
Price Target:
HK$39.00
▲(22.87% Upside)
Action:Reiterated
Date:10/21/26
The score is driven primarily by strong financial performance (high profitability, very low leverage, and solid 2025 cash generation). This is tempered by weaker technical momentum signals (negative MACD and sub-50 RSI) and a moderately expensive valuation (P/E 26.6 with only a ~1.41% dividend yield).
Positive Factors
Re-accelerating Revenue Growth
Revenue growth re-accelerated to 11% in 2025 after a flat 2024, indicating renewed commercial momentum across the portfolio. If sustained, improving top-line expansion can support investment in product launches, lifecycle management, and broader commercialization over the next several quarters.
Negative Factors
Volatile Cash Conversion
The sharp variation in operating cash flow conversion shows that reported earnings do not translate into cash consistently every year. Such volatility can complicate budgeting and reduce confidence in internally generated funding, even though 2025 cash generation was strong.
Read all positive and negative factors
Positive Factors
Negative Factors
Re-accelerating Revenue Growth
Revenue growth re-accelerated to 11% in 2025 after a flat 2024, indicating renewed commercial momentum across the portfolio. If sustained, improving top-line expansion can support investment in product launches, lifecycle management, and broader commercialization over the next several quarters.
Read all positive factors
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$196.24B
Dividend Yield1.5%
Average Volume (3M)9.63M
Price to Earnings (P/E)25.0
Beta (1Y)0.57
Revenue Growth24.97%
EPS Growth43.23%
CountryHK
Employees9,643
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.10
Shares Outstanding6,064,150,000
10 Day Avg. Volume13,373,894
30 Day Avg. Volume9,629,106
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$47.29Price Target Upside48.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)1.08
Revenue Forecast (FY)HK$16.99B
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic area...
How the Company Makes Money
Hansoh primarily makes money by selling pharmaceutical products (mainly prescription medicines) in mainland China. Revenue is generated from (1) in-house manufactured finished drugs sold to customers via the company’s commercialization network and...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.90B | 15.03B | 12.26B | 10.10B | 9.38B | 9.94B |
| Gross Profit | 14.38B | 13.51B | 11.16B | 9.07B | 8.51B | 9.06B |
| EBITDA | 6.33B | 5.79B | 4.30B | 4.20B | 2.94B | 3.08B |
| Net Income | 6.68B | 5.56B | 4.37B | 3.28B | 2.58B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 46.60B | 39.92B | 31.66B | 33.04B | 30.00B | 27.16B |
| Cash, Cash Equivalents and Short-Term Investments | 37.38B | 31.58B | 23.39B | 24.86B | 21.63B | 18.94B |
| Total Debt | 4.23B | 105.14M | 117.89M | 4.30B | 4.38B | 3.83B |
| Total Liabilities | 8.84B | 4.54B | 2.98B | 7.24B | 7.35B | 7.13B |
| Stockholders Equity | 37.76B | 35.38B | 28.68B | 25.79B | 22.65B | 20.03B |
Cash Flow | ||||||
| Free Cash Flow | 6.05B | 6.25B | 3.64B | 2.90B | 2.47B | 2.12B |
| Operating Cash Flow | 6.49B | 6.74B | 3.86B | 3.12B | 2.74B | 2.58B |
| Investing Cash Flow | -11.64B | -7.15B | -1.39B | 1.07B | -5.94B | -2.26B |
| Financing Cash Flow | 5.62B | 1.55B | -6.07B | -753.70M | -818.14M | 3.42B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Negative
31.74
Price Trends
33.56
Negative
32.48
Negative
34.06
Negative
Market Momentum
-0.29
Negative
47.38
Neutral
31.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Negative. The current price of 31.74 is below the 20-day moving average (MA) of 32.66, below the 50-day MA of 33.56, and below the 200-day MA of 34.06, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 31.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$196.24B | 24.96 | 18.26% | 1.50% | 24.97% | 43.23% | |
74 Outperform | HK$26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
61 Neutral | HK$23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% | |
60 Neutral | HK$18.13B | 143.19 | 1.43% | ― | -8.55% | -96.20% | |
56 Neutral | HK$65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3692
Hansoh Pharmaceutical Group Company Limited
32.36
-2.99
-8.45%
HK:0013
HUTCHMED (China)
20.78
-2.98
-12.54%
HK:0867
China Medical System Holdings
9.82
-3.65
-27.10%
HK:1513
Livzon Pharmaceutical Group
23.18
-5.02
-17.81%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.47
-6.58
-28.55%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.11
-2.26%
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Strikes Multibillion-Dollar ADC Pact With Roche to Expand Global Footprint
Oct 19, 2026
Hansoh Pharmaceutical Group has entered a strategic collaboration and license agreement with F. Hoffmann-La Roche Ltd covering a broad portfolio of Antibody-Drug Conjugate programs, including Hansoh’s preclinical assets and new projects base...
Hansoh’s Aumolertinib EU Application Validated by EMA
Oct 11, 2026
Hansoh Pharmaceutical Group has resubmitted its marketing authorization application for the targeted lung cancer therapy Aumolertinib, marketed as Aumseqa outside China, to the European Medicines Agency. The application, covering first-line and mu...
Hansoh Faces EU Setback on Aumolertinib but Vows Rapid Reapplication
Sep 27, 2026
Hansoh Pharmaceutical said the European Commission has revoked the EU marketing authorization for its lung cancer drug Aumolertinib, marketed as Aumseqa outside China, due to a procedural issue linked to the use of AstraZeneca’s TAGRISSO tri...
Hansoh Pharma’s Osteosarcoma Biologic HS-20093 Accepted for Review by China’s NMPA
Sep 24, 2026
Hansoh Pharmaceutical Group has announced that China’s National Medical Products Administration has accepted its biologics license application for HS-20093, branded as risvutatug rezetecan for injection. The therapy is intended for osteosarc...
Hansoh’s Osteosarcoma Drug HS-20093 Wins NMPA Priority Review in China
Sep 22, 2026
Hansoh Pharmaceutical announced that its drug candidate HS-20093, known as risvutatug rezetecan for injection, has been accepted into China’s National Medical Products Administration Priority Review and Approval Procedure. The indication cov...
Hansoh Pharma’s TYK2 Psoriasis Drug Clears Key Phase III Trial Milestone
Sep 20, 2026
Hansoh Pharmaceutical said its self-developed TYK2 inhibitor HS-10374 achieved significant efficacy in a pivotal Phase III trial for adults with moderate-to-severe plaque psoriasis, with markedly higher PASI 75 and sPGA 0/1 response rates versus p...
Hansoh Pharma Wins NMPA Nod for Clinical Trials of Innovative Cancer Drug HS-20197
Sep 16, 2026
Hansoh Pharmaceutical Group has received clinical trial approval from China’s National Medical Products Administration for HS-20197 for injection, a self-developed Class 1 innovative medicine. The therapy is intended for investigation in pat...
Hansoh’s Lung Cancer Drug HS-20093 Wins NMPA Priority Review
Sep 11, 2026
Hansoh Pharmaceutical Group announced that risvutatug rezetecan for injection (HS-20093), targeted at small cell lung cancer patients whose disease has progressed after prior platinum-based chemotherapy, has been accepted into the National Medical...
Hansoh Pharma’s HS-20093 ADC for Small Cell Lung Cancer Accepted by China’s NMPA
Sep 2, 2026
Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration has accepted its biologics license application for HS-20093 for injection. The drug is a proprietary B7-H3 directed antibody-drug conjugate intended ...
Hansoh boosts profit on innovative drugs as lung cancer portfolio wins EU and China approvals
Aug 26, 2026
Hansoh Pharmaceutical Group reported strong interim results for the six months ended June 30, 2026, with revenue rising 11.7% to RMB8.304 billion and innovative medicines contributing RMB7.092 billion, or 85.4% of total sales. Profit surged 35.8% ...
Hansoh Pharmaceutical Declares Interim Dividend for First Half of 2026
Aug 26, 2026
Hansoh Pharmaceutical Group Company Limited has declared an interim ordinary cash dividend of HKD 0.285 per share for the six months ended June 30, 2026, for the financial year ending December 31, 2026. The ex-dividend date is set for September 22...
Hansoh Pharma Wins NMPA Nod for Clinical Trials of New Cholesterol Drug
Aug 6, 2026
Hansoh Pharmaceutical Group said its self-developed Class 1 innovative drug candidate HS-10582, formulated as tablets, has received clinical trial approval from China’s National Medical Products Administration. The company plans to evaluate ...
Hansoh Pharmaceutical Schedules Board Meeting to Approve Interim Results and Dividend
Aug 4, 2026
Hansoh Pharmaceutical Group Company Limited plans to convene a board meeting on August 26, 2026, to review and approve its interim financial results for the six months ended June 30, 2026. The board will also consider the declaration of an interim...
Hansoh’s Osteosarcoma Drug HS-20093 Hits Phase III Target, China Filing Planned
Jul 28, 2026
Hansoh Pharmaceutical said its proprietary B7-H3 directed antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase III trial for osteosarcoma patients who had progressed or relapsed after at least two prior systemic therap...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.